12:00 AM
Feb 06, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Talactoferrin: Phase II/III discontinued

Agennix stopped the double-blind, international Phase II/III OASIS trial in patients with severe sepsis after an analysis by the study's DSMB showed that thrice-daily 15 mL oral talactoferrin plus standard of care (SOC) led to an increased rate...

Read the full 176 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >